All In MedTech

Device Trial Radar · NCT04612530

PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer

Irreversible Electroporation and Nivolumab Combined With Intratumoral Administration of a Toll-like Receptor Ligand as a Means of in Vivo Vaccination for Oligometastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

18

Planned (sponsor's estimate)

Start

Sep 1, 2020

Primary completion

Apr 1, 2023

Study completion Jun 1, 2023

Sponsor

Lead sponsor
Amsterdam UMC, location VUmcAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 3, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Irreversible electroporation is a local ablative technique used in the treatment of pancreatic cancer. In addition to its cytoreductive ability, IRE also induces a systemic immune response. However, this immune response is not potent enough to establish durable regression of the tumor. The immune response can be leveraged by combining IRE with immunotherapy. The primary aim of this study is to determine the safety of IRE + Nivolumab (arm B) and IRE + Nivolumab + CpG (arm C). The secondary aim is to assess efficacy of the experimental arms (B, C) and control arm A (Nivolumab monotherapy), based on overall and progression-free survival as well as locoregional and systemic immune modulation.

Conditions

  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer

Interventions

  • Irreversible Electroporation (IRE)Device

    Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue

  • NivolumabDrug

    Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.

  • Toll-Like Receptor 9Drug

    Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of the combination treatment IRE + immunotherapy based on adverse eventsTime frame: From randomization until 1 year later

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amsterdam University Medical Centre (location VUmc)

    Amsterdam, North Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.